Teva announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, the generic version of Boehringer Ingelheim’s Aggrenox Capsules.

Aggrenox is a combination antiplatelet agent indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo. Platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP). Aspirin inhibits platelet aggregation by irreversible inhibition of platelet cyclooxygenase and thus inhibits the generation of thromboxane A2, a powerful inducer of platelet aggregation and vasoconstriction.

RELATED: Novel Antiplatelet Agent Gets FDA Approval

Aspirin and Extended-Release Dipyridamole Capsules are available in a 25mg/200mg strength in 60-count bottles.

For more information call (888) 838-2872 or visit